This study offers a thorough exploration of critical consideration of resilience in pharmaceutical supply chains, aiming to provide a comprehensive overview of the existing literature on this subject. Given the increasing globalization, regulatory complexities, and disruptions, the pharmaceutical industry encounters unique challenges in maintaining the business continuity of supply chains. Design/Methodology/Approach: We conducted a systematic analysis of 41 documents, including articles, reviews, and conference papers, employing bibliometric methods to visualize the dataset. Findings: Our findings indicate a notable increase in literature in recent years, particularly concerning risk mitigation strategies, collaboration among supply chain stakeholders, and investments in technology-driven solutions for resilience in pharmaceutical supply chains. Furthermore, we have identified several research directions. This review emphasizes the necessity for ongoing scholarly efforts aimed at fostering pharmaceutical supply chains resilience given the post-COVID-19 situation with goal of ensuring the uninterrupted availability of essential medications to patients worldwide.